Article Text

Download PDFPDF
Infantile mediastinal neuroblastoma presenting as an oncologic emergency: usefulness of serum-based MYCN gene amplification analysis for risk stratification
  1. Masaya Suematsu,
  2. Shigeki Yagyu,
  3. Hajime Hosoi and
  4. Tomoko Iehara
  1. Department of Paediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan
  1. Correspondence to Dr Shigeki Yagyu; shigeky{at}koto.kpu-m.ac.jp

Abstract

We reported two infantile cases of mediastinal neuroblastoma with life-threatening tracheal obstructions presenting as oncologic emergencies that were successfully treated per tentative risk classification using serum-based MYCN gene amplification (MNA) analysis. Tentative risk stratification based on age, tumour location and serum-based MNA status may be useful in patients with neuroblastoma presenting as oncologic emergencies who require urgent therapy stratification but for whom tumor-based molecular diagnoses cannot be established.

  • paediatric oncology
  • neonatal and paediatric intensive care

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors All authors, MS, SY, HH and TI contributed to the design of the article. MS was involved in drafting the article subsequently, SY, HH and TI were involved in revising the draft of the article. All authors have approved the final manuscript and agree to be accountable for all aspects of the work.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.